Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa

References

1. Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ et al. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother 2017; 61:e01243–16 [View Article]
   [Google Scholar]
2. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM et al. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis 2014; 80:130–135 [View Article]
   [Google Scholar]
3. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–327 [View Article]
   [Google Scholar]
4. Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther 2017; 15:55–65 [View Article]
   [Google Scholar]
5. Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs 2018; 27:325–338 [View Article]
   [Google Scholar]
6. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet 2016; 387:296–307 [View Article]
   [Google Scholar]
7. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M et al. Surviving sepsis campaign. Crit Care Med 2017; 45:486–552 [View Article]
   [Google Scholar]
8. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour. Crit Care Med 2014; 42:1749–1755 [View Article]
   [Google Scholar]
9. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012; 56:472–478 [View Article]
   [Google Scholar]
10. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care 2015; 19:63 [View Article]
    [Google Scholar]
11. Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther 2017; 15:861–871 [View Article]
    [Google Scholar]
12. Khawcharoenporn T, Chuncharunee A, Maluangnon C, Taweesakulvashra T, Tiamsak P. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents 2018; 52:828–834 [View Article]
    [Google Scholar]
13. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29:321–347 [View Article]
    [Google Scholar]
14. Patient Safety Atlas - PSA Centers for disease control and prevention. https://gis.cdc.gov/grasp/PSA/MapView.html June 19, 2018
15. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
16. Pankey GA, Ashcraft DS, Dornelles A. Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagn Microbiol Infect Dis 2013; 77:220–226 [View Article]
    [Google Scholar]
17. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983; 11:427–433 [View Article]
    [Google Scholar]
18. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1 [View Article]
    [Google Scholar]
19. Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D et al. The Combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother 2018; 62:e01682–18 [View Article]
    [Google Scholar]
20. Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB et al. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. J Antimicrob Chemother 2018; 73:1570–1578 [View Article]
    [Google Scholar]
21. Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E et al. In Vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61:e00476–17 [View Article]
    [Google Scholar]
22. Monogue ML, Nicolau DP. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J Antimicrob Chemother 2018; 73:942–952 [View Article]
    [Google Scholar]
23. Avery LM, Nicolau DP. Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. J Antimicrob Chemother 2018; 73:2264–2265 [View Article]
    [Google Scholar]
24. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31:695–701 [View Article]
    [Google Scholar]
25. Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002; 8:37–42 [View Article]
    [Google Scholar]
26. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms E et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics 2017; 6:24 [View Article]
    [Google Scholar]
27. Hamou-Segarra M, Zamorano L, Vadlamani G, Chu M, Sanchez-Diener I et al. Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa. J Antimicrob Chemother 2017; 72:448–454 [View Article]
    [Google Scholar]
28. Díez-Aguilar M, Martínez-García L, Cantón R, Morosini MI. Is a new standard needed for diffusion methods for In vitro susceptibility testing of fosfomycin against Pseudomonas aeruginosa?. Antimicrob Agents Chemother 2016; 60:1158–1161 [View Article]
    [Google Scholar]
29. EUCAST EUCAST warnings. http://www.eucast.org/ast_of_bacteria/warnings/ May 1, 2018